Inventor
SMITH JULIANNE
FR24 patents
⚠️ This page may combine multiple inventors who share the name “SMITH JULIANNE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELLECTIS
19 patentsUS7842489B2Nov 30, 2010
Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
CELLECTIS63 citations95
US10874693B2Dec 29, 2020
CD19 specific chimeric antigen receptor and uses thereof
CELLECTIS7 citations92
US10426795B2Oct 1, 2019
Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells
CELLECTIS8 citations92
US10286007B2May 14, 2019
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS12 citations92
US10378026B2Aug 13, 2019
RNA based method to obtain stably integrated retroviral vectors
CELLECTIS6 citations84
US11274316B2Mar 15, 2022
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS2 citations83
US11077144B2Aug 3, 2021
CD19 specific chimeric antigen receptor and uses thereof
CELLECTIS7 citations83
US10517896B2Dec 31, 2019
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS2 citations83
US10363270B2Jul 30, 2019
Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapy
CELLECTIS6 citations83
US10342829B2Jul 9, 2019
Multi-chain chimeric antigen receptor and uses thereof
CELLECTIS6 citations81
US11014989B2May 25, 2021
Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
CELLECTIS2 citations73
US12577581B2Mar 17, 2026
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS0 citations72
US11891614B2Feb 6, 2024
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
CELLECTIS1 citations72
US11414674B2Aug 16, 2022
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS0 citations72
US11304975B2Apr 19, 2022
Methods for engineering allogeneic and highly active t cell for immunotherapy
CELLECTIS4 citations72
US11311575B2Apr 26, 2022
Methods for engineering highly active T cell for immunotherapy
CELLECTIS1 citations62
US11007224B2May 18, 2021
CD19 specific chimeric antigen receptor and uses thereof
CELLECTIS0 citations62
US11603539B2Mar 14, 2023
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
CELLECTIS0 citations54
US10752670B2Aug 25, 2020
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
CELLECTIS0 citations51